A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis.

Area of Science:

• Immunology
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB) remains a leading infectious cause of death globally.
• Drug-resistant strains necessitate novel therapeutic strategies beyond conventional antibiotics.
• Host-directed therapy (HDT) offers a promising avenue by modulating host immunity.

Purpose of the Study:

• To evaluate the efficacy of BI82, a monovalent SMAC mimetic, against mycobacterial infections.
• To elucidate the mechanism of action of BI82 in host cells.
• To assess the therapeutic potential of BI82 in preclinical models.

Main Methods:

• In vitro infection assays using macrophages and peripheral blood mononuclear cells.
• Ex vivo whole-blood assays with samples from TB patients and healthy donors.
• In vivo mouse infection model with oral administration of BI82.

Main Results:

• BI82 inhibited Mycobacterium bovis and Mycobacterium tuberculosis growth, showing synergy with rifampicin.
• The compound induced apoptosis via cIAP1 degradation, confirmed by caspase-3 and MLKL activation.
• BI82 treatment in mice reduced bacterial burden, improved lung pathology, and modulated T cell populations.

Conclusions:

• BI82 demonstrates a potent apoptosis-dependent mechanism against mycobacterial infections.
• Its efficacy against drug-resistant TB highlights its potential as a novel HDT candidate.
• Monovalent SMAC mimetics like BI82 show superior activity compared to bivalent compounds.